[ad_1]
(AOF) – Biosenic announces that Véronique Pomi-Schneiter is resigning “for personal reasons” from her position as Deputy CEO. This clinical-stage biotech specializing in severe autoimmune and inflammatory diseases specifies that she will, however, contribute to the transition process and continue to sit as a non-executive director on the board of directors, as well as in her capacity as executive director on the board of directors of its subsidiary, Medsenic.
General Manager François Rieger wishes her “a speedy recovery” and announces that she will maintain “a daily rhythm in accordance with her general physical condition.”
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, a priority for pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D that weigh on profitability. Sanofi has therefore announced a drop in its earnings per share in 2024 and the abandonment of its target of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to 22 billion dollars to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States will account for nearly half of global spending on oncology (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, from $5 billion to $11.8 billion.
[ad_2]
Source link -86